Bristol-Myers Squibb says it has seen no major business disruptions and expects no decrease in global demand for its drugs this year. That means the 3.5% dividend yield should stay stable, and BMY is a great value at 1.3 PEG. BMY also just got FDA approval for a multiple sclerosis drug, which could turn out to be a pretty big deal.
Most of the market has been trading based on macroeconomics, but as individual companies like BMY issue quantitative guidance, I think we're going to see more trading on company specifics. I bought a small position here and will add the dip if BMY heads south with the rest of the market next week.
Most of the market has been trading based on macroeconomics, but as individual companies like BMY issue quantitative guidance, I think we're going to see more trading on company specifics. I bought a small position here and will add the dip if BMY heads south with the rest of the market next week.
評論:
This trade has treated me very well so far.
